Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | September 30, 2026 | October 03, 2026 |
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Director | October 15, 2026 | October 16, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2036-09-30 | Direct | 1,109 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,109 · Balance 1,109 F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1: The options were granted on September 30, 2026, and are 100% vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on September 30, 2026, and are 100% vested.
F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2034-07-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying this option vest in 48 equal monthly installments following July 16, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in 48 equal monthly installments following July 16, 2024, subject to the Reporting Person's continued service on each such vesting date.
Harmony Biosciences Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14 | Direct | 21,872 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 21,872 · Balance 21,872 F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,109 | $12.29 Strike: $15.33 | $13,629.61 |
DisclosureSEC source: 0002063957-26-000009 · form4-10022026_041016.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,109 Underlying: Common Stock · 1,109 shares Expires 2036-09-30 F2 · price: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1 · derivative.exercise_date: The options were granted on September 30, 2026, and are 100% vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 69 | $15.04 Strike: $18.48 | $1,037.76 |
DisclosureSEC source: 0002063957-26-000007 · form4-07022026_040721.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69 Underlying: Common Stock · 69 shares Expires 2036-06-30 F1 · derivative.exercise_date: The options were granted on June 30, 2026, and are 100% vested. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,200 | $0.00 Strike: $17.83 | $0.00 |
DisclosureSEC source: 0002063957-26-000005 · form4-06252026_090620.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 40,200 shares Expires 2036-06-23 F1 · derivative.exercise_date: The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:18 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 21,872 | $0.00 Strike: $30.76 | $0.00 |
DisclosureSEC source: 0002063957-26-000001 · form4-05182026_080551.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,872 Underlying: Common Stock · 21,872 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 14,522 | $0.00 Strike: $34.23 | $0.00 |
DisclosureSEC source: 0001415889-25-013405 · form4-05162025_080525.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,522 Underlying: Common Stock · 14,522 shares Expires 2035-05-15 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 21:52 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 14,077 | $0.00 Strike: $32.53 | $0.00 |
DisclosureSEC source: 0001415889-25-010247 · form4-04042025_090430.xml · derivative · entry 1 Philip Ron M · CIK 0002063957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,077 Underlying: Common Stock · 14,077 shares Expires 2035-04-02 F1 · derivative.exercise_date: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.